Clinical Research at Adler Institute for Advanced Imaging

The clinical research department at Adler Institute for Advanced Imaging was established in 2007.  In 2018, the research division grew, KDK Scientific was established to assist in the management of these studies.  Adler Imaging has acted as the Principal Investigator in over 100 independent imaging studies for large pharmaceutical companies.  The majority of this research has involved PET/CT imaging utilizing novel radiopharmaceuticals to study oncologic diseases (e.g. Breast cancer, Prostate cancer, etc.), Alzheimer’s Disease along with other dementias, as well as Cardiac disease. Adler Imaging and KDK Scientific have successfully completed first in-human studies and are familiar with Phase I- IV studies.  In addition to serving as the PI on imaging trials, Adler Imaging and KDK Scientific have completed the PET/CT imaging component on over 80 therapeutic drug trials used for the treatment of various cancers, neurological diseases, cardiac disease and others.

The Adler Institute for Advanced Imaging and KDK Scientific core research staff includes Medical Director, Lee Adler,M.D., CEO and Director of  Research, Karel Kovnat, Ph.D. and Clinical Research Manager, Amy C. Paccapaniccia, PA-C. Additional staff includes three nuclear medicine technologists with more than10 years of research experience each.